Logo image of LIXT

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Price, Quote, News and Overview

NASDAQ:LIXT - Nasdaq - US5393193017 - Common Stock - Currency: USD

1.2701  -0.09 (-6.61%)

After market: 1.25 -0.02 (-1.58%)

LIXT Quote, Performance and Key Statistics

LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (2/21/2025, 8:00:02 PM)

After market: 1.25 -0.02 (-1.58%)

1.2701

-0.09 (-6.61%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.4
52 Week Low1.25
Market Cap2.86M
Shares2.25M
Float2.22M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-17 2025-03-17
IPO09-21 2007-09-21


LIXT short term performance overview.The bars show the price performance of LIXT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

LIXT long term performance overview.The bars show the price performance of LIXT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of LIXT is 1.2701 USD. In the past month the price decreased by -48.16%. In the past year, price decreased by -42.79%.

LIXTE BIOTECHNOLOGY HOLDINGS / LIXT Daily stock chart

LIXT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About LIXT

Company Profile

LIXT logo image Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The firm encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733 US

CEO: John S. Kovach

Employees: 4

Company Website: https://lixte.com/

Investor Relations: http://ir.lixte.com

Phone: 13102032902

LIXTE BIOTECHNOLOGY HOLDINGS / LIXT FAQ

What is the stock price of LIXTE BIOTECHNOLOGY HOLDINGS today?

The current stock price of LIXT is 1.2701 USD. The price decreased by -6.61% in the last trading session.


What is the ticker symbol for LIXTE BIOTECHNOLOGY HOLDINGS stock?

The exchange symbol of LIXTE BIOTECHNOLOGY HOLDINGS is LIXT and it is listed on the Nasdaq exchange.


On which exchange is LIXT stock listed?

LIXT stock is listed on the Nasdaq exchange.


What is LIXTE BIOTECHNOLOGY HOLDINGS worth?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a market capitalization of 2.86M USD. This makes LIXT a Nano Cap stock.


How many employees does LIXTE BIOTECHNOLOGY HOLDINGS have?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) currently has 4 employees.


What are the support and resistance levels for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a resistance level at 2.45. Check the full technical report for a detailed analysis of LIXT support and resistance levels.


Should I buy LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock pay dividends?

LIXT does not pay a dividend.


When does LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) report earnings?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) will report earnings on 2025-03-17.


What is the Price/Earnings (PE) ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).


What is the Short Interest ratio of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

The outstanding short interest for LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 4.32% of its float. Check the ownership tab for more information on the LIXT short interest.


LIXT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LIXT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LIXT. LIXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LIXT Financial Highlights

Over the last trailing twelve months LIXT reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS increased by 45.98% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -235.9%
ROE -292.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%10.72%
Sales Q2Q%N/A
EPS 1Y (TTM)45.98%
Revenue 1Y (TTM)N/A

LIXT Ownership and Analysts


Ownership
Inst Owners11.28%
Ins Owners8.1%
Short Float %4.32%
Short Ratio1.31
Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A